vorinostat has been researched along with Sepsis in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| " S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)." | 6.87 | A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018) |
| "SAHA treatment enhances survival and attenuates sepsis-associated coagulopathy by improving fibrin cross-linkage, rate of clot formation, platelet function, and clot strength." | 3.80 | Histone deacetylase inhibitor treatment attenuates coagulation imbalance in a lethal murine model of sepsis. ( Alam, HB; Halaweish, I; Li, Y; Liu, B; Sillesen, M; Velmahos, GC; Wu, E; Zhao, T, 2014) |
| " S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)." | 2.87 | A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018) |
| "Sepsis is a life-threatening medical emergency triggered by excessive inflammation in response to an infection." | 1.91 | Histone Deacetylase Inhibitor (SAHA) Reduces Mortality in an Endotoxemia Mouse Model by Suppressing Glycolysis. ( Ehle, C; He, Y; Heinzel, T; Iyer-Bierhoff, A; Liu, B; Liu, C; Wu, Y; Xing, S, 2023) |
| "Sepsis-associated encephalopathy (SAE), which associates with neuronal apoptosis and cognitive disorders, is a common complication of systemic sepsis." | 1.40 | Epigenetic modulation of neuronal apoptosis and cognitive functions in sepsis-associated encephalopathy. ( Cai, S; Fang, J; Lian, Y; Wen, P; Xie, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Y | 1 |
| He, Y | 1 |
| Liu, C | 1 |
| Ehle, C | 1 |
| Iyer-Bierhoff, A | 1 |
| Liu, B | 3 |
| Heinzel, T | 1 |
| Xing, S | 1 |
| Persky, DO | 1 |
| Li, H | 1 |
| Rimsza, LM | 1 |
| Barr, PM | 1 |
| Popplewell, LL | 1 |
| Bane, CL | 1 |
| Von Gehr, A | 1 |
| LeBlanc, M | 1 |
| Fisher, RI | 1 |
| Smith, SM | 1 |
| Friedberg, JW | 1 |
| Fang, J | 1 |
| Lian, Y | 1 |
| Xie, K | 1 |
| Cai, S | 1 |
| Wen, P | 1 |
| Zhao, T | 2 |
| Li, Y | 2 |
| Wu, E | 1 |
| Sillesen, M | 1 |
| Velmahos, GC | 1 |
| Halaweish, I | 1 |
| Alam, HB | 2 |
| Liu, Z | 1 |
| Chong, W | 1 |
| Wang, Y | 1 |
1 trial available for vorinostat and Sepsis
| Article | Year |
|---|---|
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cy | 2018 |
4 other studies available for vorinostat and Sepsis
| Article | Year |
|---|---|
Histone Deacetylase Inhibitor (SAHA) Reduces Mortality in an Endotoxemia Mouse Model by Suppressing Glycolysis.
Topics: Animals; Endotoxemia; Histone Deacetylase Inhibitors; Hydroxamic Acids; Mice; Sepsis; Vorinostat | 2023 |
Epigenetic modulation of neuronal apoptosis and cognitive functions in sepsis-associated encephalopathy.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Brain Diseases; Cells, Cultured; Cogn | 2014 |
Histone deacetylase inhibitor treatment attenuates coagulation imbalance in a lethal murine model of sepsis.
Topics: Animals; Blood Coagulation; Blood Coagulation Disorders; Blood Platelets; Disease Models, Animal; Di | 2014 |
Citrullinated histone H3: a novel target for the treatment of sepsis.
Topics: Animals; Antibodies, Neutralizing; Biomarkers; Citrulline; Disease Models, Animal; Enzyme Inhibitors | 2014 |